Free Trial

ProPhase Labs (PRPH) Competitors

$3.12
-0.09 (-2.80%)
(As of 07/19/2024 ET)

PRPH vs. LPTX, ME, ACRV, EPIX, IMMP, STTK, VTYX, ABEO, GBIO, and ELYM

Should you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Leap Therapeutics (LPTX), 23andMe (ME), Acrivon Therapeutics (ACRV), ESSA Pharma (EPIX), Immutep (IMMP), Shattuck Labs (STTK), Ventyx Biosciences (VTYX), Abeona Therapeutics (ABEO), Generation Bio (GBIO), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical preparations" industry.

ProPhase Labs vs.

Leap Therapeutics (NASDAQ:LPTX) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, community ranking, dividends, analyst recommendations, profitability and media sentiment.

30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are owned by institutional investors. 11.3% of Leap Therapeutics shares are owned by insiders. Comparatively, 20.7% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ProPhase Labs has higher revenue and earnings than Leap Therapeutics. ProPhase Labs is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Leap Therapeutics$1.50M35.33-$81.41M-$2.39-0.87
ProPhase Labs$44.38M1.34-$16.78M-$1.08-2.89

Leap Therapeutics received 177 more outperform votes than ProPhase Labs when rated by MarketBeat users. Likewise, 68.79% of users gave Leap Therapeutics an outperform vote while only 50.00% of users gave ProPhase Labs an outperform vote.

CompanyUnderperformOutperform
Leap TherapeuticsOutperform Votes
291
68.79%
Underperform Votes
132
31.21%
ProPhase LabsOutperform Votes
114
50.00%
Underperform Votes
114
50.00%

Leap Therapeutics presently has a consensus target price of $10.40, indicating a potential upside of 402.42%. ProPhase Labs has a consensus target price of $11.00, indicating a potential upside of 252.56%. Given ProPhase Labs' higher probable upside, analysts clearly believe Leap Therapeutics is more favorable than ProPhase Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Leap Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
ProPhase Labs
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Leap Therapeutics and Leap Therapeutics both had 1 articles in the media. ProPhase Labs' average media sentiment score of 1.94 beat Leap Therapeutics' score of 0.00 indicating that Leap Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Leap Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
ProPhase Labs
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Leap Therapeutics has a net margin of 0.00% compared to Leap Therapeutics' net margin of -82.18%. Leap Therapeutics' return on equity of -44.96% beat ProPhase Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Leap TherapeuticsN/A -81.00% -68.93%
ProPhase Labs -82.18%-44.96%-25.88%

Leap Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500.

Summary

Leap Therapeutics beats ProPhase Labs on 10 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PRPH vs. The Competition

MetricProPhase LabsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$59.53M$7.08B$5.33B$8.23B
Dividend YieldN/A2.70%2.75%3.95%
P/E Ratio-2.8920.49138.5418.24
Price / Sales1.34277.862,144.6375.95
Price / CashN/A32.1936.3933.93
Price / Book1.145.734.874.42
Net Income-$16.78M$147.21M$111.99M$216.15M
7 Day Performance-5.31%-2.42%-0.66%-0.11%
1 Month Performance-28.93%5.54%7.25%5.51%
1 Year Performance-55.68%-4.12%6.30%1.70%

ProPhase Labs Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LPTX
Leap Therapeutics
3.5188 of 5 stars
3.52 / 5 stars
$2.24
+2.8%
$10.40
+364.3%
-31.7%$57.34M$1.50M-0.9454Positive News
ME
23andMe
0.0857 of 5 stars
0.09 / 5 stars
$0.51
+4.1%
$0.47
-7.2%
-75.7%$248.37M$219.64M-0.36769News Coverage
ACRV
Acrivon Therapeutics
2.7438 of 5 stars
2.74 / 5 stars
$7.94
+6.3%
$22.57
+184.3%
-43.8%$245.19MN/A-2.7658Short Interest ↑
Positive News
EPIX
ESSA Pharma
0.9903 of 5 stars
0.99 / 5 stars
$5.52
-1.6%
$16.50
+198.9%
+92.5%$244.87MN/A-8.7650Gap Up
IMMP
Immutep
0.7923 of 5 stars
0.79 / 5 stars
$2.03
-0.5%
$8.00
+294.1%
-14.5%$241.33M$3.50M0.002,021Short Interest ↑
Analyst Revision
News Coverage
Gap Up
STTK
Shattuck Labs
1.0426 of 5 stars
1.04 / 5 stars
$4.85
+5.7%
$11.00
+126.8%
+63.6%$230.62M$1.66M-2.5175Positive News
VTYX
Ventyx Biosciences
1.3101 of 5 stars
1.31 / 5 stars
$3.20
+12.7%
$15.75
+392.2%
-92.9%$225.60MN/A-0.9930News Coverage
ABEO
Abeona Therapeutics
4.2635 of 5 stars
4.26 / 5 stars
$5.34
-0.9%
$19.00
+255.8%
+36.6%$218.73M$3.50M-1.67N/APositive News
GBIO
Generation Bio
3.3465 of 5 stars
3.35 / 5 stars
$3.19
+8.9%
$8.00
+150.8%
-45.2%$212.23M$5.90M-1.25174Short Interest ↑
Positive News
ELYM
Eliem Therapeutics
0.5173 of 5 stars
0.52 / 5 stars
$7.06
+1.0%
N/A+145.0%$210.04MN/A-13.329Insider Selling
News Coverage

Related Companies and Tools

This page (NASDAQ:PRPH) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners